Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Aus. Peptide Conferenc...Aus. Peptide Conference
Not Confirmed
Not Confirmed
12-17 October, 2025
World Vaccine CongressWorld Vaccine Congress
Not Confirmed
Not Confirmed
13-16 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Aus. Peptide Conferenc...Aus. Peptide Conference
Industry Trade Show
Not Confirmed
12-17 October, 2025
World Vaccine CongressWorld Vaccine Congress
Industry Trade Show
Not Confirmed
13-16 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-are-building-capabilities-to-stay-ahead-of-the-curve-and-align-with-future-needs-of-global-healthcare
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india
29 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/29/3157655/0/en/MBX-Biosciences-to-Participate-in-the-Stifel-2025-Virtual-Cardiometabolic-Forum.html
22 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/22/3153770/0/en/MBX-Biosciences-Announces-Once-Weekly-Canvuparatide-Achieved-Primary-Endpoint-in-Phase-2-Trial-with-63-Responder-Rate-at-12-Weeks-79-Responder-Rate-at-6-Months-in-Open-Label-Extens.html
22 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/22/3154306/0/en/MBX-Biosciences-Announces-Proposed-Public-Offering.html
19 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/19/3153399/0/en/MBX-Biosciences-to-Provide-Topline-Results-from-its-Phase-2-Trial-of-Potential-Once-Weekly-Canvuparatide-for-Hypoparathyroidism-HP-on-Monday-September-22.html
04 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/04/3144426/0/en/MBX-Biosciences-Doses-First-Participant-in-Phase-1-Trial-of-MBX-4291-for-the-Treatment-of-Obesity.html
07 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/07/3129192/0/en/MBX-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Corporate-Highlights.html
Details:
MBX 4291 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Lead Product(s): MBX 4291,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2025
Lead Product(s) : MBX 4291,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX 4291 Safety, Tolerability, PK/PD In Adults with Obesity
Details : MBX 4291 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2025
Details:
MBX 1416 is a Hormone drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Lead Product(s): MBX 1416,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 19, 2025
Lead Product(s) : MBX 1416,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Subcutaneous MBX 1416 In Postbariatric Hypoglycemia Patients
Details : MBX 1416 is a Hormone drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 19, 2025
Details:
MBX 4291 is a long-acting GLP1/GIP Receptor co-agonist prodrug, which is currently being evaluated for the treatment of obesity.
Lead Product(s): MBX 4291,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 16, 2025
Lead Product(s) : MBX 4291,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Submits IND for MBX 4291 to Treat Obesity with GLP1/GIP Co-Agonist
Details : MBX 4291 is a long-acting GLP1/GIP Receptor co-agonist prodrug, which is currently being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 16, 2025
Details:
MBX 2109 (canvuparatide) is a long-acting PTH peptide prodrug which is currently being evaluated for the treatment of patients with hypoparathyroidism.
Lead Product(s): Canvuparatide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2025
Lead Product(s) : Canvuparatide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Completes Enrollment in Phase 2 Avail Trial for MBX 2109
Details : MBX 2109 (canvuparatide) is a long-acting PTH peptide prodrug which is currently being evaluated for the treatment of patients with hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 03, 2025
Details:
MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): MBX 1416,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2025
Lead Product(s) : MBX 1416,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Announces Positive Phase 1 Results for MBX 1416 in Hypoglycemia
Details : MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 07, 2025
Details:
MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): MBX 1416,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024
Lead Product(s) : MBX 1416,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Completes Phase 1 MBX 1416 Study for Post-Bariatric Hypoglycemia
Details : MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 18, 2024
Details:
The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Lead Product(s): Canvuparatide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $187.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2024
Lead Product(s) : Canvuparatide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $187.7 million
Deal Type : Public Offering
MBX Biosciences Closes Upsized IPO, Underwriters Purchase Additional Shares
Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 16, 2024
Details:
The proceeds will advance the development of MBX 2109 and MBX 1416, two clinical programs, MBX 4291. MBX 2109 is designed as a potential long-acting hormone replacement therapy for hypoparathyroidism.
Lead Product(s): Canvuparatide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $163.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2024
Lead Product(s) : Canvuparatide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $163.2 million
Deal Type : Public Offering
MBX Biosciences Announces Pricing of Initial Public Offering
Details : The proceeds will advance the development of MBX 2109 and MBX 1416, two clinical programs, MBX 4291. MBX 2109 is designed as a potential long-acting hormone replacement therapy for hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 12, 2024
Details:
The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Lead Product(s): Canvuparatide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $163.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2024
Lead Product(s) : Canvuparatide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $163.2 million
Deal Type : Public Offering
MBX Biosciences Announces Pricing of Initial Public Offering
Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 12, 2024
Details:
The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Lead Product(s): Canvuparatide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 26, 2024
Lead Product(s) : Canvuparatide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
MBX files for IPO, Seeking Cash to Take Challenger to Ascendis' Yorvipath into Phase 3
Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
August 26, 2024
ABOUT THIS PAGE